drugset
drugset / Trial / NCT03244358

Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer

NCT03244358 ↗

Phase 2 Terminated 12 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of Epalrestat in the treatment of metastatic triple negative breast

Timeline

Start
2017-03-01
Primary completion
2020-12-01
Completion
2020-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Epalrestat Small molecule 50 mg —

Indications

triple-negative breast carcinoma